中国实用外科杂志2024，Vol.44Issue(10)：1095-1098,4.DOI:10.19538/j.cjps.issn1005-2208.2024.10.03
免疫治疗时代胃癌围手术期治疗若干焦点问题
Key issues in perioperative treatment of gastric cancer in the era of immunotherapy
摘要
Abstract
Immunotherapy represented by PD-1/PD-L1 monoclonal antibody has significantly improved the survival outcome of patients with advanced gastric cancer.Neoadjuvant chemotherapy+D2 radical resection for gastric cancer is one of the current standard treatment strategies for gastric cancer.In recent years,a number of studies on perioperative chemotherapy combined with immunotherapy for gastric cancer have shown that perioperative chemotherapy+immunotherapy significantly improves the pCR rate.The ATTRACTION-5 and KEYNOTE585 studies did not meet expectations,and the short-term efficacy of MATTERHONE is more significant and worth looking forward to.The screening of immunodominant populations and precision treatment are the main problems of perioperative immunotherapy.关键词
局部进展期胃癌/围手术期/免疫治疗Key words
locally advanced gastric cancer/perioperative period/immunotherapy分类
医药卫生引用本文复制引用
丁学伟,梁寒..免疫治疗时代胃癌围手术期治疗若干焦点问题[J].中国实用外科杂志,2024,44(10):1095-1098,4.基金项目
天津市医学重点学科(专科)建设项目(No.TJYXZDXK-009A) （专科）
